Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 41.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,900 shares of the biopharmaceutical company’s stock after selling 4,100 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,623,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. TD Asset Management Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after purchasing an additional 27,592 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after buying an additional 16,756 shares during the period. Avoro Capital Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 33.3% during the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after buying an additional 100,000 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after buying an additional 1,000 shares during the period. Finally, Eagle Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 1.1 %

NASDAQ:ALNY opened at $251.81 on Friday. The company’s 50 day moving average is $269.49 and its 200-day moving average is $243.89. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market cap of $32.48 billion, a price-to-earnings ratio of -96.11 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on ALNY shares. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,370 shares of company stock worth $2,100,703 in the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.